Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07298668

Cardiovascular Risk Factors in Middle Eastern Patients With Stroke

Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Low-Density-Lipoprotein-cholesterol Level Nervous System Diseases Risk Factors Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.

These clinically relevant issues have not been studied extensively in the Middle East where most of the studies in atherosclerotic cardiovascular disease have focused on acute coronary syndrome more than stroke. Exploring new information on risk factors of stroke in this region that helps fill some of the knowledge gaps.

Stroke has been attributed, in the majority of cases, to the traditional four standard modifiable risk factors of hypertension, type 2 diabetes, dyslipidemia, and cigarette smoking. However, ethnicity and geography account for the interregional differences of the prevalence of risk factors in patients with stroke.

The Jo-SMMART ill evaluate risk factors in 2000 stroke patients in Jordan as a representative of the Middle Eastern population, the prevalence of those with none of the 4 risk factors and the differences in clinical profiles and demographic features on those with risk factors and those with no risk factors. Lipid profile and use of lipid lowering agents will also be evaluated, and furthermore the die0fferneces between young vs old, and men vs women stroke patients ill be addressed.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of stroke upon admission to the hospital
  • Adult aged 18 years or older
  • Available lipid profile on hospital admission

Exclusion criteria

  • Stroke diagnosis unconfirmed
  • age younger than 18 years
  • No available lipid profile on admission

Treatment and study plan

Primary outcomes

  1. Prevalence of hypertension in stroke patients (survey interview)

    Time frame: Baseline

    BP more 140/90 or known diagnosis of high blood pressure or patient already on blood pressure medication

  2. Prevalence of type 2 diabetes in stroke patients (survey interview)

    Time frame: BASELINE

    HbA1c more than 6.5%, or known diagnosis of type 2 diabetes or patient already on anti diabetes medications

  3. Prevalence of elevated serum level of low density lipoprotein cholesterol in stroke patients (survey interview)

    Time frame: BASELINE

    Elevated serum level of low density lipoprotein cholesterol > 55 mg/dl or patient already on lipid lowering medication

  4. Prevalence of current cigarette smoking in stroke patients (survey interview)

    Time frame: BASELINE

    Known current cigarette smoking of any number of cigarettes per day

  5. Use of lipid lowering therapy (survey interview)

    Time frame: BASELINE

    Current use of statin, ezitimibe, PCS9 inhibitor of small interfering RNA agent to lower the LDL-C

Study contacts

Contact information is provided by the study sponsor or research team.

Ayman Hammoudeh, MD, FACC

CONTACT

[email protected]

065001000

Laith Habahbeh, MD

CONTACT

[email protected]

065001000

Sponsors and collaborators

Lead sponsor

Jordan Collaborating Cardiology Group

Other

Registry information

Official study title

Standard Modifiable Risk Factors in Middle Eastern Patients With Stroke (Jo-SMMART Study)

Acronym: JoSMMART

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Dec 23, 2025
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.